Belzeaux Raoul, Lefebvre Marie-Noëlle, Lazzari Anne, Le Carpentier Tifenn, Consoloni Julia-Lou, Zendjidjian Xavier, Abbar Mocrane, Courtet Philippe, Naudin Jean, Boucraut José, Gressens Pierre, Glaichenhaus Nicolas, Ibrahim El Chérif
Aix-Marseille Univ., CNRS, CRN2M-UMR7286, Marseille, France; Pôle de Psychiatrie, Assistance Publique-Hôpitaux de Marseille, Marseille, France; Fondation FondaMental, Fondation de Recherche et de Soins en Santé Mentale, Créteil, France.
CIC-CPCET, AP-HM, Hôpital La Timone, Marseille, France.
Psychoneuroendocrinology. 2017 Jan;75:72-82. doi: 10.1016/j.psyneuen.2016.10.010. Epub 2016 Oct 20.
Cytokines produced by both immune and non-immune cells are likely to play roles in the development and/or progression of psychiatric disorders. Indeed, many investigators have compared the blood cytokine levels in psychiatric patients with those of healthy controls or monitored their levels in patients during disease progression to identify biomarkers. Nevertheless, very few studies have confirmed that such cytokines remain stable in healthy individuals through periods of weeks and months. This is an important issue to consider before using blood cytokine levels as biomarkers of disease traits, disease state, or treatment response. Although multiplex assay technology represents an advance in identifying biomarkers because it allows simultaneous examination of large panels of analytes from a small volume of sample, it is necessary to verify whether these assays yield enough sensitivity and reproducibility when applied to the blood from neuropsychiatric patients. Therefore, we compared two multiplex immunoassays, the bead-based Luminex (Bio-Rad) and the electro-chemiluminescence-based V-plex (MesoScaleDiscovery), for the detection and quantification of 31 cytokines, chemokines and growth factors in both the sera and plasma of patients with major depressive episodes (MDE) and age- and sex-matched healthy control subjects during a 30-week period. Although both platforms exhibited low coefficients of variability (CV) between the duplicates in the calibration curves, the linearity was better in general for the V-PLEX platform. However, neither platform was able to detect the absolute values for all of the tested analytes. Among the 16 analytes that were detected by both assays, the intra-assay reproducibility was in general better with the V-PLEX platform. Although it is not a general rule that the results from sera and plasma will be correlated, consistent results were more frequent with the V-PLEX platform. Furthermore, the V-PLEX results were more consistent with the gold standard ELISA simplex assay for IL-6 in both sera and plasma. The intra-individual variability of the measurements, among the sera and plasma for the 4 samples harvested from each healthy individual, was low for Eotaxin, G-CSF, IL-4, IL-7, IL-9, IL-12p40, IL-12p70, IL-15, MIP-1β, PDGF-BB, TNF, TNF-β and VEGF, but intermediate or high for IFN-γ, IL-6, IL-8, IL-10, and IP10. Together, these data suggest that extreme caution is needed in translating the results of multiplex cytokine profiling into biomarker discovery in psychiatry.
免疫细胞和非免疫细胞产生的细胞因子可能在精神疾病的发生和/或发展中发挥作用。事实上,许多研究人员比较了精神疾病患者与健康对照者的血液细胞因子水平,或者在疾病进展过程中监测患者的细胞因子水平,以确定生物标志物。然而,很少有研究证实这些细胞因子在健康个体中在数周和数月的时间内保持稳定。在将血液细胞因子水平用作疾病特征、疾病状态或治疗反应的生物标志物之前,这是一个需要考虑的重要问题。尽管多重检测技术在识别生物标志物方面是一项进步,因为它允许从少量样本中同时检测大量分析物,但有必要验证这些检测方法应用于神经精神疾病患者的血液时是否具有足够的灵敏度和可重复性。因此,我们比较了两种多重免疫检测方法,基于微珠的Luminex(伯乐公司)和基于电化学发光的V-plex(MesoScaleDiscovery),用于检测和定量重度抑郁发作(MDE)患者以及年龄和性别匹配的健康对照者在30周期间血清和血浆中的31种细胞因子、趋化因子和生长因子。尽管两个平台在校准曲线中的重复样本之间的变异系数(CV)都很低,但总体而言V-PLEX平台的线性更好。然而,两个平台都无法检测到所有测试分析物的绝对值。在两种检测方法都能检测到的16种分析物中,V-PLEX平台的批内重复性总体上更好。虽然血清和血浆的结果不一定相关,但V-PLEX平台得到一致结果的情况更常见。此外,V-PLEX在血清和血浆中检测IL-6的结果与金标准ELISA单克隆检测结果更一致。对于从每个健康个体采集的4份样本的血清和血浆,嗜酸性粒细胞趋化因子、粒细胞集落刺激因子、白细胞介素-4、白细胞介素-7、白细胞介素-9、白细胞介素-12p40、白细胞介素-12p70、白细胞介素-15、巨噬细胞炎性蛋白-1β、血小板衍生生长因子-BB、肿瘤坏死因子、肿瘤坏死因子-β和血管内皮生长因子的测量个体内变异性较低,但干扰素-γ、白细胞介素-6、白细胞介素-8、白细胞介素-10和干扰素诱导蛋白10的变异性为中等或较高。总之,这些数据表明,在将多重细胞因子谱分析结果转化为精神科生物标志物发现时需要极其谨慎。